Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review

Ibrutinib is an orally available, small-molecule tyrosine kinase inhibitor. Its main purpose is to inhibit Bruton’s tyrosine kinase (BTK), an enzyme that is crucial in B cell development. It is FDA approved for the treatment of certain hematological malignancies. Several promising off-target drug ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Metzler, Julian Matthias, Burla, Laurin, Fink, Daniel, Imesch, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312555/
https://www.ncbi.nlm.nih.gov/pubmed/32532074
http://dx.doi.org/10.3390/ijms21114154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312555/
https://www.ncbi.nlm.nih.gov/pubmed/32532074
http://dx.doi.org/10.3390/ijms21114154

Ejemplares similares